Comment on

• Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

  Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M. Bonnefoi H, et al. Ann Oncol. 2003 Mar;14(3):406-13. doi: 10.1093/annonc/mdg108. Ann Oncol. 2003. PMID: 12598346 Clinical Trial.
• Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer.

  Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F. Anelli A, et al. Ann Oncol. 2003 Mar;14(3):428-32. doi: 10.1093/annonc/mdg104. Ann Oncol. 2003. PMID: 12598349 Clinical Trial.